Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes.
Company profile
Ticker
SYK
Exchange
Website
CEO
Kevin Lobo
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
2Hip Holdings SAS • Aimago SA • Alcott Indemnity Company • Arrinex, Inc. • Berchtold + Fritz GmbH • Berchtold Corporation • Berchtold GmbH & Co. KG • Berchtold Holding Switzerland GmbH • BioMimetic Therapeutics USA, Inc. • BioMimetic Therapeutics, LLC ...
IRS number
381239739
SYK stock data
Analyst ratings and price targets
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
28 Mar 23
DEF 14A
Definitive proxy
28 Mar 23
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
10 Feb 23
10-K
2022 FY
Annual report
10 Feb 23
8-K
Stryker Reports 2022 Operating Results and 2023 Outlook
31 Jan 23
8-K
Amendments to Articles of Incorporation or Bylaws
15 Nov 22
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
1 Nov 22
10-Q
2022 Q3
Quarterly report
1 Nov 22
8-K
Stryker Reports Third Quarter 2022 Operating Results
31 Oct 22
10-Q
2022 Q2
Quarterly report
27 Jul 22
Transcripts
SYK
Earnings call transcript
2022 Q4
31 Jan 23
SYK
Earnings call transcript
2022 Q3
1 Nov 22
SYK
Earnings call transcript
2022 Q2
27 Jul 22
SYK
Earnings call transcript
2022 Q1
29 Apr 22
SYK
Earnings call transcript
2021 Q4
28 Jan 22
SYK
Earnings call transcript
2021 Q3
29 Oct 21
SYK
Earnings call transcript
2021 Q2
28 Jul 21
SYK
Earnings call transcript
2021 Q1
28 Apr 21
SYK
Earnings call transcript
2020 Q4
28 Jan 21
SYK
Earnings call transcript
2020 Q3
29 Oct 20
Latest ownership filings
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.84 bn | 1.84 bn | 1.84 bn | 1.84 bn | 1.84 bn | 1.84 bn |
| Cash burn (monthly) | (no burn) | 91.67 mm | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | n/a | 268.37 mm | n/a | n/a | n/a | n/a |
| Cash remaining | n/a | 1.58 bn | n/a | n/a | n/a | n/a |
| Runway (months of cash) | n/a | 17.2 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2022
79.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 1600 |
| Opened positions | 190 |
| Closed positions | 90 |
| Increased positions | 563 |
| Reduced positions | 576 |
| 13F shares | Current |
|---|---|
| Total value | 73.15 tn |
| Total shares | 299.69 mm |
| Total puts | 777.40 k |
| Total calls | 1.44 mm |
| Total put/call ratio | 0.5 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 30.25 mm | $7.39 tn |
| BLK Blackrock | 24.50 mm | $5.99 tn |
| Greenleaf Trust | 19.64 mm | $4.81 tn |
| Wellington Management | 17.03 mm | $4.16 tn |
| T. Rowe Price | 14.96 mm | $3.67 tn |
| STT State Street | 14.12 mm | $3.46 tn |
| Capital Research Global Investors | 14.08 mm | $3.44 tn |
| BK Bank Of New York Mellon | 6.58 mm | $1.61 tn |
| MS Morgan Stanley | 5.98 mm | $1.46 tn |
| Geode Capital Management | 5.84 mm | $1.43 tn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 21 Mar 23 | Becker Yin C | Common Stock | Payment of exercise | Dispose F | No | No | 276.83 | 417 | 115.44 k | 22,079 |
| 21 Mar 23 | Becker Yin C | Common Stock | Option exercise | Acquire M | No | No | 0 | 22 | 0.00 | 22,496 |
| 21 Mar 23 | Becker Yin C | Dividend Equivalents Common Stock | Option exercise | Dispose M | No | No | 0 | 22 | 0.00 | 0 |
| 21 Mar 23 | Berry William E Jr | Common Stock | Payment of exercise | Dispose F | No | No | 276.83 | 337 | 93.29 k | 3,482 |
| 21 Mar 23 | Boehnlein Glenn S | Common Stock | Payment of exercise | Dispose F | No | No | 276.83 | 2,715 | 751.59 k | 5,187 |
| 21 Mar 23 | Boehnlein Glenn S | Common Stock | Option exercise | Acquire M | No | No | 0 | 149 | 0.00 | 7,902 |
| 21 Mar 23 | Boehnlein Glenn S | Dividend Equivalents Common Stock | Option exercise | Dispose M | No | No | 0 | 149 | 0.00 | 0 |
| 21 Mar 23 | Fink M Kathryn | Common Stock | Payment of exercise | Dispose F | No | No | 276.83 | 752 | 208.18 k | 10,222 |
| 21 Mar 23 | Fink M Kathryn | Common Stock | Option exercise | Acquire M | No | No | 0 | 46 | 0.00 | 10,974 |
| 21 Mar 23 | Fink M Kathryn | Dividend Equivalents Common Stock | Option exercise | Dispose M | No | No | 0 | 46 | 0.00 | 0 |
News
Canaccord Genuity Reiterates Hold on Stryker, Maintains $250 Price Target
28 Mar 23
Argus Research Maintains Buy on Stryker, Raises Price Target to $285
21 Feb 23
Stryker's Q Guidance System Scores FDA Clearance For Cranial Applications
17 Feb 23
Stryker's Q Guidance System For Cranial Applications Receives FDA Clearance
17 Feb 23
General Motors, Bank of America And 2 Other Stocks Insiders Are Selling
7 Feb 23
Press releases
Stryker announces Annual Meeting of Shareholders
28 Mar 23
CD NXT power tool system empowers surgeons through real-time depth measurement
2 Mar 23
Stryker's Q Guidance System for cranial applications receives FDA clearance
17 Feb 23
Stryker declares a $0.75 per share quarterly dividend
9 Feb 23
Thinking about trading options or stock in Meta, Baidu, Apple, Stryker, or NVIDIA?
1 Feb 23